Home » Stocks » PRTK

Paratek Pharmaceuticals, Inc. (PRTK)

Stock Price: $5.42 USD -0.10 (-1.81%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $5.43 +0.01 (0.19%) Jul 29, 5:50 PM
Market Cap 259.04M
Revenue (ttm) 55.43M
Net Income (ttm) -87.27M
Shares Out 46.66M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE 135.14
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $5.42
Previous Close $5.52
Change ($) -0.10
Change (%) -1.81%
Day's Open 5.58
Day's Range 5.40 - 5.58
Day's Volume 124,571
52-Week Range 4.11 - 11.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

-- First BARDA Procurement has been Delivered and Revenue will be Recognized in Second Quarter 2021 -- First BARDA Procurement has been Delivered and Revenue will be Recognized in Second Quarter 2021

1 month ago - GlobeNewsWire

GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management

1 month ago - Business Wire

Do you agree with analysts on these penny stocks? The post 9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290% appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other stocks mentioned: CDEV, GTBP, NCMI, SYRS
1 month ago - PennyStocks

The company reduced its 2021 revenue outlook.

1 month ago - The Motley Fool

Paratek Pharmaceuticals Inc (NASDAQ: PRTK) has initiated Phase 2b trial evaluating Nuzyra (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease caused by Mycobacterium abscessus comple...

1 month ago - Benzinga

-- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment

1 month ago - GlobeNewsWire

BOSTON, June 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

1 month ago - GlobeNewsWire

The company gets off to a roaring start in June with an important FDA nod.

1 month ago - The Motley Fool

BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

1 month ago - GlobeNewsWire

The FDA has approved Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) supplemental marketing application for the oral-only dosing regimen of Nuzyra for Community-Acquired Bacterial Pneumonia (CABP). The app...

1 month ago - Benzinga

- Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion

1 month ago - GlobeNewsWire

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...

2 months ago - GlobeNewsWire

Paratek (PRTK) delivered earnings and revenue surprises of -77.27% and -49.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 40.91% year over year to ($0.39), which missed the es...

2 months ago - Benzinga

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $13.2 Million in the First Quarter 2021; 6% Increase Over the Fourth Quarter 2020 -- BARDA has Initiated the First Procurement of NUZYRA Valued at ~...

2 months ago - GlobeNewsWire

Paratek (PRTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

3 months ago - Zacks Investment Research

Paratek (PRTK) delivered earnings and revenue surprises of -712.50% and -59.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

-- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 -- NUZYRA Expansion into the Primary Care Setting in 2021

5 months ago - GlobeNewsWire

BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

5 months ago - GlobeNewsWire

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

5 months ago - GlobeNewsWire

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...

Other stocks mentioned: ARGX, EYPT, GILD, GRCL, INO, LLY, ZLAB
6 months ago - Seeking Alpha

Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc. Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.

6 months ago - GlobeNewsWire

The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), position boosts i...

Other stocks mentioned: BHC, CHMA
7 months ago - GuruFocus

BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

7 months ago - GlobeNewsWire

Nuzyra launch trajectory is top of class compared with other antibiotics. BARDA deal signed late 2019 is worth $285M.

7 months ago - Seeking Alpha

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

8 months ago - GlobeNewsWire

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Paratek (PRTK) delivered earnings and revenue surprises of 24.59% and 14.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

9 months ago - GlobeNewsWire

Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/X...

9 months ago - GlobeNewsWire

Paratek Pharmaceuticals: Undervalued Antibiotics Play With A Fighting Chance

10 months ago - Seeking Alpha

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav...

10 months ago - GlobeNewsWire

BOSTON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav...

10 months ago - GlobeNewsWire

Paratek Pharmaceuticals, Inc.(PRTK) CEO Evan Loh on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Paratek (PRTK) delivered earnings and revenue surprises of -278.57% and -72.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.3% in pre-market trading after the company reported Q2 results.

11 months ago - Benzinga

BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

11 months ago - GlobeNewsWire

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

1 year ago - GlobeNewsWire

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

BOSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin...

1 year ago - GlobeNewsWire

Paratek Plods Along

1 year ago - Seeking Alpha

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Paratek (PRTK) delivered earnings and revenue surprises of 20.48% and 2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.1% in pre-market trading after the company reported Q1 results.

1 year ago - Benzinga

As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals

1 year ago - Zacks Investment Research

Purchase of the first 2,500 treatment courses of NUZYRA expected in the first half of 2020 Purchase of the first 2,500 treatment courses of NUZYRA expected in the first half of 2020

1 year ago - GlobeNewsWire

Paratek Revenue Ramp-Up Is Underappreciated By The Market And Should Drive Stock Price Gains

1 year ago - Seeking Alpha

Paratek Pharmaceuticals: A Bright 2020 Ahead

1 year ago - Seeking Alpha

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracy... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Evan Loh
Employees
196
Stock Exchange
NASDAQ
Ticker Symbol
PRTK
Full Company Profile

Financial Performance

In 2020, PRTK's revenue was $46.92 million, an increase of 183.63% compared to the previous year's $16.54 million. Losses were -$96.54 million, -25.04% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for PRTK stock is "Strong Buy." The 12-month stock price forecast is 19.60, which is an increase of 261.62% from the latest price.

Price Target
$19.60
(261.62% upside)
Analyst Consensus: Strong Buy